BioSpace News Archive

Merck KGaA, Darmstadt, Germany announced that data across several modalities and mechanisms targeting difficult-to-treat cancers will be presented at the 2019 American Society of Clinical Oncology Annual Meeting, May 31–June 4, Chicago, IL, US.

Oncopeptides AB announced that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma have been selected for poster presentation at the 2019 American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4 in Chicago.

Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its Morphoseq™ technology and announcing the appointment to CEO of Nick McCooke, who built and led the team at Solexa that pioneered NGS prior to the company being acquired by Illumina.

Oral presentation on the results of sintilimab for relapsed/refractory extranodal NK/T cell lymphoma

Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board of Directors.

ProBioGen AG, a premier German service & technology provider for complex biologics and Vaccitech, Ltd., a spin-out company from the University of Oxford’s Jenner Institute, one of the most renowned vaccine research centers in the world, today jointly announced signing a license agreement

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of EarlyCDT—Lung in Israel.

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced its revenues and cash position for the first three-months of 2019.

Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, announced today that the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial is the recipient of the prestigious David Sackett Trial of the Year Award, presented annually by the Society for Clinical Trials (SCT)

emotive, the award-winning global healthcare communications agency, is delighted to announce the creation of a new business unit dedicated to advanced therapies.